EPIX · ESSA Pharma Inc

-

Please sign in to comment on EPIX

1 Comment

Admin

3 years, 7 months ago

ESSA Pharma Inc is currently in a long term uptrend where the price is trading 37.0% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

ESSA Pharma Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 41.2% to $-7M since the same quarter in the previous year.

Finally, its free cash flow fell by 17.3% to $-4M since the same quarter in the previous year.

Based on the above factors, ESSA Pharma Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	CA29668H7085
Industry	Biotechnology
Sector	Healthcare

Market Cap	129M
Dividend Yield	0.0%
Beta	2.11
Target Price	21.6
PE Ratio	None

ABOUT

ESSA Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. The company develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. It has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX · ESSA Pharma Inc

-

ESSA Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest ESSA Pharma Inc using a moving average strategy